Preclinical Research

North Brunswick, N.J. – October 30, 2026 -- All five antibody-deficient mice treated with Lactiga's LCTG-001 survived influenza infection, compared with two of five in the control group, according to a peer-reviewed preclinical study conducted by McMaster University scientists in collaboration with Lactiga US, Inc.

The research was published in Science Advances on October 14, 2026. LCTG-001 is a nasal antibody treatment made from secretory immunoglobulin A (sIgA) purified from donated human breast milk. Lactiga is developing it for patients with common variable immunodeficiency (CVID) who keep getting respiratory infections despite existing therapies.

COPENHAGEN – October 29, 2026 -- HERVolution Therapeutics ApS published peer-reviewed data in the Journal of Translational Medicine showing HERV-K expression across the majority of 43 cancer types in RNA sequencing data from 1,353 patients, backing the target rationale for its lead program, IPT-001.

HERV-K expression spans nearly all cancer types examined

The analysis used data from the Copenhagen Prospective Personalized Oncology study (CoPPO, NCT02290522), which enrolled patients with advanced, predominantly pre-treated cancer. Most patients showed more than 100 HML-2 reads per million total reads across the 43 cancer types, cancers of unknown primary and unclassified tumors. The authors say this extends earlier indication-specific reports.